Mucosal Melanoma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

BRAF
BRAF Codon 600 Missense
BRAF V600E
KIT
KIT Mutation
NRAS
NRAS Mutation
PD-L1 Expression
PD-L1 High Expression
PD-L1 Low Expression
PD-L1 Overexpression
TYRP1 Expression

Overview

NCI Definition: A melanoma that arises from a mucosal site. [1]

Mucosal melanomas most frequently harbor alterations in NF1, TP53, KIT, CDKN2A, and NRAS [2].

Most Commonly Altered Genes in Mucosal Melanoma

CDKN2A Loss, NRAS Mutation, KIT Mutation, TP53 Mutation, and TP53 Missense are the most common alterations in mucosal melanoma [2].

Top Alterations in Mucosal Melanoma

Clinical Trials

View Clinical Trials for Mucosal Melanoma

There are 20 clinical trials for mucosal melanoma, of which 17 are open and 3 are completed or closed. Of the trials that contain mucosal melanoma as an inclusion criterion, 5 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), and 13 are phase 2 (11 open).

BRAF, PD-L1, and TYRP1 are the most frequent gene inclusion criteria for mucosal melanoma clinical trials [3].

Trials Investigating Mucosal Melanoma by Gene and Recruiting Status

Nivolumab, pembrolizumab, and ipilimumab are the most common interventions in mucosal melanoma clinical trials.

Drugs Being Investigated in Mucosal Melanoma Trials by Recruiting Status

Significant Genes in Mucosal Melanoma

ALK +

ALK is altered in 2.31% of mucosal melanoma patients [2].

ALK is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ALK status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF +

BRAF is altered in 11.36% of mucosal melanoma patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for mucosal melanoma, of which 1 is open and 1 is closed. Of the trials that contain BRAF status and mucosal melanoma as inclusion criteria, 2 are phase 2 (1 open) [3].

CCND1 +

CCND1 is altered in 11.61% of mucosal melanoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 +

CDK4 is altered in 7.69% of mucosal melanoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 +

CDK6 is altered in 1.29% of mucosal melanoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A +

CDKN2A is altered in 17.54% of mucosal melanoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

GNA11 +

GNA11 is altered in 1.16% of mucosal melanoma patients [2].

GNA11 is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains GNA11 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

GNAQ +

GNAQ is altered in 2.29% of mucosal melanoma patients [2].

GNAQ is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains GNAQ status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS +

HRAS is altered in 2.31% of mucosal melanoma patients [2].

HRAS is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT +

KIT is altered in 18.02% of mucosal melanoma patients [2].

KIT is an inclusion eligibility criterion in 2 clinical trials for mucosal melanoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and mucosal melanoma as inclusion criteria, 2 are phase 2 (1 open) [3].

KRAS +

KRAS is altered in 8.52% of mucosal melanoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAP2K1 +

MAP2K1 is altered in 0.62% of mucosal melanoma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET +

MET is altered in 2.31% of mucosal melanoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NF1 +

NF1 is altered in 29.38% of mucosal melanoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS +

NRAS is altered in 14.37% of mucosal melanoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 +

ROS1 is altered in 9.68% of mucosal melanoma patients [2].

ROS1 is an inclusion eligibility criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ROS1 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [3].

Disease Details

Parent(s)

Non-Cutaneous Melanoma

Children

Mucosal Melanoma of the Urethra, Cervical Melanoma, Mucosal Melanoma of the Head and Neck, Esophageal Melanoma, and Vulvar/Vaginal Mucosal Melanoma

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.